NRX Pharmaceuticals annual ebitda
2024
2025
NRX Pharmaceuticals EBITDA Growth & History (NRXP)
NRX Pharmaceuticals's calculated EBITDA was −$16.2M for fiscal 2025.
View full NRX Pharmaceuticals company overviewNRX Pharmaceuticals annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$16.2M | $2.3M | — |
| 2024 | 2024-12-31 | −$18.5M | — | — |
NRX Pharmaceuticals quarterly ebitda
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$6.4M | −$2.7M | — |
| Q1 2026 | 2026-03-31 | −$4.7M | −$833,000 | — |
| Q4 2025 | 2025-12-31 | −$4.6M | −$1.6M | — |
| Q3 2025 | 2025-09-30 | −$4.0M | — | — |
| Q2 2025 | 2025-06-30 | −$3.7M | — | — |
| Q1 2025 | 2025-03-31 | −$3.8M | — | — |
| Q3 2024 | 2024-09-30 | −$3.0M | — | — |
NRX Pharmaceuticals ebitda trends
Across the available reported history, NRX Pharmaceuticals's ebitda increased from −$18.5M to −$16.2M, a change of $2.3M. The latest reported quarter, Q2 2026, shows −$6.4M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NRX Pharmaceuticals filings at SEC.gov ↗